研究業績

分子生物・病理学的研究

乳腺の病態を解明する基礎的研究。

  1. 1.Iida M, Tsuboi K, Niwa T, Ishida T, Hayashi SI. Compensatory role of insulin-like growth factor 1 receptor in estrogen receptor signaling pathway and possible therapeutic target for hormone therapy-resistant breast cancer. Breast Cancer. 2018 Oct 16. doi: 10.1007/s12282-018-0922-0. [Epub ahead of print]
  2. 2.Yanai A, Harada R, Iwata R, Yoshikawa T, Ishikawa Y, Furumoto S, Ishida T, Yanai K. Site-Specific Labeling of F-18 Proteins Using a Supplemented Cell-Free Protein Synthesis System and O-2-[18F]Fluoroethyl-L-Tyrosine: [18F]FET-HER2 Affibody Molecule. Mol Imaging Biol. 2018 Aug 15. doi: 10.1007/s11307-018-1266-z. [Epub ahead of print]
  3. 3.Yanai A, Itoh M, Hirakawa H, Yanai K, Tashiro M, Harada R, Yoshikawa A, Yamamoto S, Ohuchi N, Ishida T. Newly-Developed Positron Emission Mammography (PEM) Device for the Detection of Small Breast Cancer. Tohoku J Exp Med. 2018 May;245(1):13-19. doi: 10.1620/tjem.245.13.
  4. 4.Watanabe G, Chiba N, Nomizu T, Furuta A, Sato K, Miyashita M, Tada H, Suzuki A, Ohuchi N, Ishida T. Increased centrosome number in BRCA-related breast cancer specimens determined by immunofluorescence analysis. Cancer Sci. 2018 Jun;109(6):2027-2035. doi: 10.1111/cas.13595. Epub 2018 May 15.
  5. 5.Miyashita M, Tada H, Suzuki A, Watanabe G, Hirakawa H, Amari M, Kakugawa Y, Kawai M, Furuta A, Sato K, Yoshida R, Ebata A, Sasano H, Jingu K, Ohuchi N, Ishida T. Minimal impact of postmastectomy radiation therapy on locoregional recurrence for breast cancer patients with 1 to 3 positive lymph nodes in the modern treatment era. Surg Oncol. 2017 Jun;26(2):163-170. doi: 10.1016/j.suronc.2017.03.003. Epub 2017 Mar 16.
  6. 6.Tamaki K, Fukuyama AK, Terukina S, Kamada Y, Uehara K, Arakaki M, Yamashiro K, Miyashita M, Ishida T, McNamara KM, Ohuchi N, Tamaki N, Sasano H. Randomized trial of aromatherapy versus conventional care for breast cancer patients during perioperative periods. Breast Cancer Res Treat. 2017 Apr;162(3):523-531. doi: 10.1007/s10549-017-4134-7. Epub 2017 Feb 8.
  7. 7.Kakugawa Y, Tada H, Kawai M, Suzuki T, Nishino Y, Kanemura S, Ishida T, Ohuchi N, Minami Y. Associations of obesity and physical activity with serum and intratumoral sex steroid hormone levels among postmenopausal women with breast cancer: analysis of paired serum and tumor tissue samples. Breast Cancer Res Treat. 2017 Feb;162(1):115-125. doi: 10.1007/s10549-016-4094-3. Epub 2017 Jan 2.
  8. 8.Sato F, Arinaga Y, Sato N, Ishida T, Ohuchi N. The Perioperative Educational Program for Improving Upper Arm Dysfunction in Patients with Breast Cancer at 1-Year Follow-Up: A Prospective, Controlled Trial. Tohoku J Exp Med. 2016 Mar;238(3):229-36. doi: 10.1620/tjem.238.229.
  9. 9.Kawai M, Tomotaki A, Miyata H, Iwamoto T, Niikura N, Anan K, Hayashi N, Aogi K, Ishida T, Masuoka H, Iijima K, Masuda S, Tsugawa K, Kinoshita T, Nakamura S, Tokuda Y.Body mass index and survival after diagnosis of invasive breast cancer: a study based on the Japanese National Clinical Database-Breast Cancer Registry. Cancer Med. 2016 Jun;5(6):1328-40. doi: 10.1002/cam4.678. Epub 2016 Feb 29.
  10. 10.Nakagawa S, Miki Y, Miyashita M, Hata S, Takahashi Y, Rai Y, Sagara Y, Ohi Y, Hirakawa H, Tamaki K, Ishida T, Watanabe M, Suzuki T, Ohuchi N, Sasano H. Tumor microenvironment in invasive lobular carcinoma: possible therapeutic targets. Breast Cancer Res Treat. 2016 Jan;155(1):65-75. doi: 10.1007/s10549-015-3668-9. Epub 2015 Dec 29.
  11. 11.Miyashita M, Sasano H, Tamaki K, Hirakawa H, Takahashi Y, Nakagawa S, Watanabe G, Tada H, Suzuki A, Ohuchi N, Ishida T. Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study. Breast Cancer Res. 2015 Sep 4;17:124. doi: 10.1186/s13058-015-0632-x.
  12. 12.Kakugawa Y, Kawai M, Nishino Y, Fukamachi K, Ishida T, Ohuchi N, Minami Y. Smoking and survival after breast cancer diagnosis in Japanese women: A prospective cohort study. Cancer Sci. 2015 Aug;106(8):1066-74. doi: 10.1111/cas.12716. Epub 2015 Jul 14.
  13. 13.Watanabe G, Ishida T, Furuta A, Takahashi S, Watanabe M, Nakata H, Kato S, Ishioka C, Ohuchi N. Combined Immunohistochemistry of PLK1, p21, and p53 for Predicting TP53 Status: An Independent Prognostic Factor of Breast Cancer. Am J Surg Pathol. 2015 Aug;39(8):1026-34. doi: 10.1097/PAS.0000000000000386.
  14. 14.Tamaki K, Tamaki N, Kamada Y, Uehara K, Zaha H, Onomura M, Ueda M, Kurashita K, Miyazato K, Higa J, Miyara K, Shiraishi M, Murayama S, Ishida T; 7th Okinawa Breast Oncology Meeting Members. Can we improve breast cancer mortality in Okinawa? Consensus of the 7th Okinawa Breast Oncology Meeting. Tohoku J Exp Med. 2015 Feb;235(2):111-5. doi: 10.1620/tjem.235.111.
  15. 15.Nemoto N, Shibahara Y, Tada H, Uchida K, McNamara KM, Chan MS, Watanabe M, Tamaki K, Miyashita M, Miki Y, Gonda K, Ishida T, Ohuchi N, Sasano H. Clinical significance of subtype classification in metastatic lymph nodes of breast cancer patients undergoing neoadjuvant chemotherapy. Int J Biol Markers. 2015 May 26;30(2):e174-83. doi: 10.5301/jbm.5000128.
  16. 16.Miyashita M, Sasano H, Tamaki K, Chan M, Hirakawa H, Suzuki A, Tada H, Watanabe G, Nemoto N, Nakagawa S, Ishida T, Ohuchi N. Tumor-infiltrating CD8+ and FOXP3+ lymphocytes in triple-negative breast cancer: its correlation with pathological complete response to neoadjuvant chemotherapy. Breast Cancer Res Treat. 2014 Dec;148(3):525-34. doi: 10.1007/s10549-014-3197-y. Epub 2014 Nov 14.
  17. 17.Sato K, Miyashita M, Ishida T, Suzuki A, Tada H, Watanabe G, Sato-Tadano A, Watanabe M, Ohuchi N. Prognostic significance of the progesterone receptor status in Ki67-high and -low Luminal B-like HER2-negative breast cancers. Breast Cancer. 2016 Mar;23(2):310-7. doi: 10.1007/s12282-014-0575-6. Epub 2014 Nov 8.
  18. 18.Tamaki K, Tamaki N, Terukina S, Kamada Y, Uehara K, Arakaki M, Miyashita M, Ishida T, McNamara KM, Ohuchi N, Sasano H. The correlation between body mass index and breast cancer risk or estrogen receptor status in Okinawan women. Tohoku J Exp Med. 2014 Nov;234(3):169-74.
  19. 19.Fujii R, Hanamura T, Suzuki T, Gohno T, Shibahara Y, Niwa T, Yamaguchi Y, Ohnuki K, Kakugawa Y, Hirakawa H, Ishida T, Sasano H, Ohuchi N, Hayashi S. Increased androgen receptor activity and cell proliferation in aromatase inhibitor-resistant breast carcinoma. J Steroid Biochem Mol Biol. 2014 Oct;144 Pt B:513-22. doi: 10.1016/j.jsbmb.2014.08.019. Epub 2014 Aug 29.
  20. 20.Sato F, Ishida T, Ohuchi N. The perioperative educational program for improving upper arm dysfunction in patients with breast cancer: a controlled trial. Tohoku J Exp Med. 2014 Feb;232(2):115-22.
  21. 21.Tamaki K, Tamaki N, Kamada Y, Uehara K, Miyashita M, Sm Chan M, Ishida T, Ohuchi N, Sasano H. Non-invasive evaluation of axillary lymph node status in breast cancer patients using shear wave elastography. Tohoku J Exp Med. 2013 Nov;231(3):211-6.
  22. 22.Sato-Tadano A, Suzuki T, Amari M, Takagi K, Miki Y, Tamaki K, Watanabe M, Ishida T, Sasano H, Ohuchi N. Hexokinase II in breast carcinoma: a potent prognostic factor associated with hypoxia-inducible factor-1α and Ki-67. Cancer Sci. 2013 Oct;104(10):1380-8. doi: 10.1111/cas.12238. Epub 2013 Aug 21.
  23. 23.Miyashita M, Amano G, Ishida T, Tamaki K, Uchimura F, Ono T, Yajima M, Kuriya Y, Ohuchi N. The Clinical Significance of Breast MRI in the Management of Ductal Carcinoma In Situ Diagnosed on Needle Biopsy. Jpn J Clin Oncol. 2013 Apr 16.
  24. 24.Suzuki A, Ishida T, Ohuchi N. [Current status and problems of breast cancer screening in Japan]. Nihon Rinsho. 2012 Sep;70 Suppl 7:780-4. Japanese.
  25. 25.Tada H, Ishida T, Suzuki A, Ohuchi N. [Elements of informed consent in patients with diagnosed breast cancer]. Nihon Rinsho. 2012 Sep;70 Suppl 7:747-50. Japanese.
  26. 26.Watanabe G, Ishida T, Ohuchi N. [Adjuvant endocrine therapy for postmenopausal women]. Nihon Rinsho. 2012 Sep;70 Suppl 7:636-40. Japanese.
  27. 27.Tamaki K, Tamaki N, Kamada Y, Uehara K, Ohuchi N, Miyashita M, Ishida T, Sasano H. Clinical significance following breast conservation therapy with or without irradiation in breast cancer patients. Jpn J Clin Oncol. 2013 Mar;43(3):251-7.
  28. 28.Tamaki K, Ishida T, Tamaki N, Kamada Y, Uehara K, Miyashita M, Amari M, Tadano-Sato A, Takahashi Y, Watanabe M, McNamara K, Ohuchi N, Sasano H. Analysis of clinically relevant values of Ki-67 labeling index in Japanese breast cancer patients. Breast Cancer. 2012 Jul 11.
  29. 29.Ebata A, Suzuki T, Takagi K, Miki Y, Onodera Y, Nakamura Y, Fujishima F, Ishida K, Watanabe M, Tamaki K, Ishida T, Ohuchi N, Sasano H. Oestrogen-induced genes in ductal carcinoma in situ: their comparison with invasive ductal carcinoma. Endocr Relat Cancer. 2012 Jul 18;19(4):485-96.
  30. 30.Tamaki K, Ishida T, Miyashita M, Amari M, Ohuchi N, Kamada Y, Uehara K, Tamaki N, Sasano H. Breast ultrasonographic and histopathological characteristics without any mammographic abnormalities. Jpn J Clin Oncol. 2012 Mar;42(3):168-74.
  31. 31.Tamaki K, Ishida T, Miyashita M, Amari M, Mori N, Ohuchi N, Tamaki N, Sasano H. Multidetector row helical computed tomography for invasive ductal carcinoma of the breast: correlation between radiological findings and the corresponding biological characteristics of patients. Cancer Sci. 2012 Jan;103(1):67-72.
  32. 32.Miyashita M, Ishida T, Ishida K, Tamaki K, Amari M, Watanabe M, Ohuchi N, Sasano H. Histopathological subclassification of triple negative breast cancer using prognostic scoring system: five variables as candidates. Virchows Arch. 2011 Jan;458(1):65-72.
  33. 33.Tamaki K, Ishida T, Miyashita M, Amari M, Ohuchi N, Tamaki N, Sasano H. Correlation between mammographic findings and corresponding histopathology: potential predictors for biological characteristics of breast diseases. Cancer Sci. 2011 Dec;102(12):2179-85.
  34. 34.Tamaki K, Sasano H, Maruo Y, Takahashi Y, Miyashita M, Moriya T, Sato Y, Hirakawa H, Tamaki N, Watanabe M, Ishida T, Ohuchi N. Vasohibin-1 as a potential predictor of aggressive behavior of ductal carcinoma in situ of the breast. Cancer Sci. 2010 Apr;101(4):1051-8.
  35. 35.Tamaki K, Sasano H, Ishida T, Miyashita M, Takeda M, Amari M, Tamaki N, Ohuchi N. Comparison of core needle biopsy (CNB) and surgical specimens for accurate preoperative evaluation of ER, PgR and HER2 status of breast cancer patients. Cancer Sci. 2010 Sep;101(9):2074-9.
  36. 36.Oka K, Suzuki T, Onodera Y, Miki Y, Takagi K, Nagasaki S, Akahira J, Ishida T, Watanabe M, Hirakawa H, Ohuchi N, Sasano H. Nudix-type motif 2 in human breast carcinoma: a potent prognostic factor associated with cell proliferation. Int J Cancer. 2011 Apr 15;128(8):1770-82.
  37. 37.Tamaki K, Sasano H, Ishida T, Ishida K, Miyashita M, Takeda M, Amari M, Harada-Shoji N, Kawai M, Hayase T, Tamaki N, Ohuchi N. The correlation between ultrasonographic findings and pathologic features in breast disorders. Jpn J Clin Oncol. 2010 Oct;40(10):905-12.
  38. 38.Fukamachi K, Ishida T, Usami S, Takeda M, Watanabe M, Sasano H, Ohuchi N. Total-circumference intraoperative frozen section analysis reduces margin-positive rate in breast-conservation surgery. Jpn J Clin Oncol. 2010 Jun;40(6):513-20.
  39. 39.Amari M, Ishida T, Takeda M, Ohuchi N. Capecitabine monotherapy is efficient and safe in all line settings in patients with metastatic and advanced breast cancer. Jpn J Clin Oncol. 2010 Mar;40(3):188-93.
  40. 40.Watanabe G, Kato S, Nakata H, Ishida T, Ohuchi N, Ishioka C. alphaB-crystallin: a novel p53-target gene required for p53-dependent apoptosis. Cancer Sci. 2009 Dec;100(12):2368-75.
  41. 41.Ishida T, Kiba T, Takeda M, Matsuyama K, Teramukai S, Ishiwata R, Masuda N, Takatsuka Y, Noguchi S, Ishioka C, Fukushima M, Ohuchi N. Phase II study of capecitabine and trastuzumab combination chemotherapy in patients with HER2 overexpressing metastatic breast cancers resistant to both anthracyclines and taxanes. Cancer Chemother Pharmacol. 2009 Jul;64(2):361-9.
  42. 42.Ishida T, Tamaki K, Ohuchi N. [The current state of chemotherapy for breast cancer--the divergence between its continuation or discontinuation in outpatient chemotherapy]. Gan To Kagaku Ryoho. 2008 Dec;35 Suppl 1:97-9. Japanese.
  43. 43.Tamaki K, Moriya T, Sato Y, Ishida T, Maruo Y, Yoshinaga K, Ohuchi N, Sasano H. Vasohibin-1 in human breast carcinoma: a potential negative feedback regulator of angiogenesis. Cancer Sci. 2009 Jan;100(1):88-94.
  44. 44.Harada-Shoji N, Yamada T, Ishida T, Amari M, Suzuki A, Moriya T, Ohuchi N. Usefulness of lesion image mapping with multidetector-row helical computed tomography using a dedicated skin marker in breast-conserving surgery. Eur Radiol. 2009 Apr;19(4):868-74.
  45. 45..Ishida T, Takeda M, Suzuki A, Amari M, Moriya T, Ohuchi N. Significance of irradiation in breast-conserving treatment: comparison of local recurrence rates in irradiated and nonirradiated groups. Int J Clin Oncol. 2008 Feb;13(1):12-7.
  46. 46.Ohuchi N. Current topics in breast cancer clinical research, 2007. Int J Clin Oncol. 2008 Feb;13(1):1-2.
  47. 47.Ito M, Moriya T, Ishida T, Usami S, Kasajima A, Sasano H, Ohuchi N. Significance of pathological evaluation for lymphatic vessel invasion in invasive breast cancer. Breast Cancer. 2007;14(4):381-7.
  48. 48.Usami S, Moriya T, Amari M, Suzuki A, Ishida T, Sasano H, Ohuchi N. Reliability of prognostic factors in breast carcinoma determined by core needle biopsy. Jpn J Clin Oncol. 2007 Apr;37(4):250-5
  49. 49.Usami S, Moriya T, Kasajima A, Suzuki A, Ishida T, Sasano H, Ohuchi N. Pathological aspects of core needle biopsy for non-palpable breast lesions. Breast Cancer. 2005;12(4):272-8. Review.
  50. 50.Amano G, Yajima M, Moroboshi Y, Kuriya Y, Ohuchi N. MRI accurately depicts underlying DCIS in a patient with Paget's disease of the breast without palpable mass and mammography findings. Jpn J Clin Oncol. 2005 Mar;35(3):149-53.
  51. 51.Takeda M, Ishida T, Ohnuki K, Suzuki A, Kiyohara H, Moriya T, Ohuchi N. Breast conserving surgery with primary volume replacement using a lateral tissue flap. Breast Cancer. 2005;12(1):16-20.
  52. 52.Moriya T, Hirakawa H, Suzuki T, Sasano H, Ohuchi N. Ductal Carcinoma in situ and related lesions of the breast: recent advances in pathology practice. Breast Cancer. 2004;11(4):325-33. Review.
  53. 53.Takeda M, Ishida T, Ohnuki K, Suzuki A, Sakayori M, Ishioka C, Nomizu T, Noguchi S, Matsubara Y, Ohuchi N. Collaboration of breast cancer clinic and genetic counseling division for BRCA1 and BRCA2 mutation family in Japan. Breast Cancer. 2004;11(1):30-2.
  54. 54.Amari M, Moriya T, Ishida T, Harada Y, Ohnuki K, Takeda M, Sasano H, Horii A, Ohuchi N. Loss of heterozygosity analyses of asynchronous lesions of ductal carcinoma in situ and invasive ductal carcinoma of the human breast. Jpn J Clin Oncol. 2003 Nov;33(11):556-62.
  55. 55.Ishida T, Ohnuki K, Takeda M, Suzuki A, Ohuchi N. [Treatment strategy for liver metastasis from breast cancer]. Nihon Geka Gakkai Zasshi. 2003 Oct;104(10):707-10. Japanese.
  56. 56.Shiraishi K, Kato S, Han SY, Liu W, Otsuka K, Sakayori M, Ishida T, Takeda M, Kanamaru R, Ohuchi N, Ishioka C. Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library. J Biol Chem. 2004 Jan 2;279(1):348-55.
  57. 57.Ishida T, Furuta A, Moriya T, Ohuchi N. Pathological assessment of intraductal spread of carcinoma in relation to surgical margin state in breast-conserving surgery. Jpn J Clin Oncol. 2003 Apr;33(4):161-6.
  58. 58.Yoshida R, Ohuchi N, Kimura N. Clinicopathological study of chromogranin A, B and BRCA1 expression in node-negative breast carcinoma. Oncol Rep. 2002 Nov-Dec;9(6):1363-7.
  59. 59.Kimura N, Yoshida R, Shiraishi S, Pilichowska M, Ohuchi N. Chromogranin A and chromogranin B in noninvasive and invasive breast carcinoma. Endocr Pathol. 2002 Summer;13(2):117-22.

<< 前のページに戻る

ページのトップへ戻る